| Janssen-Cilag AG - Trevicta 263 mg/1.315 ml, Depot-Injektionssuspension in einer Fertigspritze |
| 66054 | | 02 | | Trevicta 263 mg/1.315 ml | | Depot-Injektionssuspension in einer Fertigspritze | | N05AX13 | | Paliperidone | | 16.11.2016 | | |
|
| Composition |
| paliperidonum 263 mg ut paliperidoni palmitas 410 mg, polysorbatum 20, macrogolum 4000, acidum citricum monohydricum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad suspensionem pro 1.315 ml corresp. natrium 5.40 mg. |
| Packungsbestandteile |
| Retardsuspension zur intramuskulären Injektion | | | | | | | | Active Agent | Dose |
|---|
| Paliperidonum | 263mg / 1.315ml |
| | BAG: Active Agent | Dose |
|---|
| Paliperidonum | 263 mg |
| | | | Inactive agents | Dose |
|---|
| Citric Acid Monohydrate | | | Macrogol | 4000 | | Sodium Dihydrogenophosphate Monohydrate | | | Sodium Hydroxide | | | Polysorbatum 20 | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | | 938.22 | 1036.80 | B | SL | Yes |
|
